A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis

被引：0
|
作者：
Luchi, Monica [1 ]
Fidelus-Gort, Rosanne [1 ]
Douglas, Diane [1 ]
Zhang, Haifeng [1 ]
Flores, Robert [1 ]
Newton, Robert [1 ]
Scherle, Peggy [1 ]
Yeleswaram, Swamy [1 ]
Chen, Xuejun [1 ]
Sandor, Victor [1 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797
引用
收藏
页码：S765 / S766
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
    Mease, Philip
    Coates, Laura C.
    Helliwell, Philip S.
    Stanislavchuk, Mykola
    Rychlewska-Hanczewska, Anna
    Dudek, Anna
    Abi-Saab, Walid
    Tasset, Chantal
    Meuleners, Luc
    Harrison, Pille
    Besuyen, Robin
    Van der Aa, Annegret
    Mozaffarian, Neelufar
    Greer, Joy M.
    Kunder, Rebecca
    Van den Bosch, Filip
    Gladman, Dafna D.
    LANCET, 2018, 392 (10162): : 2367 - 2377
  • [22] An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents
    Genovese, Mark C.
    Kavanaugh, Arthur
    Weinblatt, Michael E.
    Peterfy, Charles
    DiCarlo, Julie
    White, Michael L.
    O'Brien, Maryann
    Grossbard, Elliott B.
    Magilavy, Daniel B.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (02): : 337 - 345
  • [23] EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE
    Skljarevski, V.
    Oakes, T.
    Ferguson, M.
    Zhang, Q.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    Goadsby, P.
    Dodick, D.
    CEPHALALGIA, 2016, 36 : 42 - 42
  • [24] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Goadsby, P.
    Dodick, D. W.
    HEADACHE, 2016, 56 : 68 - 68
  • [25] A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
    Sands, B.
    Sandborn, W.
    Feagan, B. G.
    Lichtenstein, G.
    Zhang, H.
    Szapary, P.
    Panes, J.
    Vermeire, S.
    O'Brien, C.
    Dewey, J.
    Yang, Z.
    Johanns, J.
    Strauss, R.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S71 - S72
  • [26] A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC
    Sands, Bruce
    Sandborn, William
    Feagan, Brian
    Lichtenstein, Gary
    Zhang, Hongyan
    Szapary, Philippe
    Panes, Julian
    Vermeire, Severine
    Christopher, O. O'' Brien
    Dewey, Julia
    Yang, Zijiang
    Johanns, Jewel
    Strauss, Richard
    Marano, Colleen
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S8 - S8
  • [27] Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
    Peeva, Elena
    Hodge, Martin R.
    Kieras, Elizabeth
    Vazquez, Michael L.
    Goteti, Kosalaram
    Tarabar, Sanela G.
    Alvey, Christine W.
    Banfield, Christopher
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) : 1776 - 1788
  • [28] A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis - Radiologic progression and correlation of Genant and Larsen scores
    Jiang, YB
    Genant, HK
    Watt, I
    Cobby, M
    Bresnihan, B
    Aitchison, R
    McCabe, D
    ARTHRITIS AND RHEUMATISM, 2000, 43 (05): : 1001 - 1009
  • [29] A randomized, placebo-controlled, dose-ranging study to deltermine the efficacy, safety, and tolerability of perampanel, a selective amPA receptor antagonist, in patients with advanced Parkinson's disease
    Oertel, Wolfgang
    Eggert, Karla
    Squillacote, David
    NEUROLOGY, 2008, 70 (11) : A423 - A424
  • [30] Recombinant human interleukin-1 receptor antagonist reduces radiologic progression in patients with rheumatoid arthritis in a multicenter, double-blind, dose-ranging, randomized and placebo controlled study
    Jiang, Y
    Genant, HK
    Watt, I
    Cobby, M
    Bresnihan, B
    Aitchison, R
    McCabe, D
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 106 - 106
12345